Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Marts 2020

Planlagt Fastgjort Låst Flyttet Genmab
1.5k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • A Offline
    A Offline
    AaBforever
    wrote on sidst redigeret af
    #227

    Det er svært at være daytrader i disse tider...nogle dage skal man starte ud med bull andre dage bear. Men hvis man rammer er der penge i Genmab.

    1 Reply Last reply
    0
    • T Offline
      T Offline
      Thetreble
      wrote on sidst redigeret af
      #228

      Sarclisa fra Sanofi bliver billigere end Genmab - er dette middel en trussel mod dara salget ?

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #229

        Ja i tredie linie er det. Vincent Rajkumar har på Twitter meddelt at han vil bruge Sarclisa i Pom/Dex kombien hvis det er billigere...

        1 Reply Last reply
        0
        • G Offline
          G Offline
          GeorgeBest
          wrote on sidst redigeret af
          #230

          Sarclisa er kun godkendt til tredie linie plus patienter, så i første og anden linie er det ikke en trussel, og det er langt det største marked

          1 Reply Last reply
          0
          • G Offline
            G Offline
            GeorgeBest
            wrote on sidst redigeret af
            #231

            Nogen der ved hvornår Sarclisa kan blive godkendt i 1. og 2. linie?

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #232
              1. linje dette her fase 3 - Ikema: https://www.clinicaltrials.gov/ct2/show/NCT03275285?term=isatuximab+mm&draw=2&rank=4
              1 Reply Last reply
              0
              • BulderB Offline
                BulderB Offline
                Bulder
                wrote on sidst redigeret af
                #233

                Det eneste 1. linje jeg har kunnet finde er dette fase 1: https://www.clinicaltrials.gov/ct2/show/NCT02513186?term=isatuximab+mm&draw=2&rank=2

                1 Reply Last reply
                0
                • BulderB Offline
                  BulderB Offline
                  Bulder
                  wrote on sidst redigeret af
                  #234

                  Så Ikema i 2. linje bliver det næste med primary completion til november og tidligst godkendelse sidst i 2021.

                  1 Reply Last reply
                  0
                  • G Offline
                    G Offline
                    GeorgeBest
                    wrote on sidst redigeret af
                    #235

                    Tak Bulder

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #236

                      this NKTCL trial was recently completed; should we expect a Ph III trial to be started? https://clinicaltrials.gov/ct2/show/NCT02927925?term=NKTCL+AND+daratumumab&draw=2&rank=1

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        GeorgeBest
                        wrote on sidst redigeret af
                        #237

                        There were some years ago stories about fantastic outcome for some patients with NKTCL who received dara. But since then it has been quite.

                        1 Reply Last reply
                        0
                        • BulderB Offline
                          BulderB Offline
                          Bulder
                          wrote on sidst redigeret af
                          #238

                          Conclusions: DARA 16 mg/kg was well tolerated with no new safety concerns, and only 2 patients discontinuing due to TEAEs. DARA monotherapy demonstrated an encouraging response rate (ORR: 25%) in pts with R/R NKTCL and warrants further study in this poor prognosis pt population. https://ashpublications.org/blood/article/134/Supplement_1/1568/427350/Daratumumab-Monotherapy-for-Patients-with-Relapsed

                          1 Reply Last reply
                          0
                          • BulderB Offline
                            BulderB Offline
                            Bulder
                            wrote on sidst redigeret af
                            #239

                            Spørgsmålet er så om det var opmuntrende nok

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #240

                              1513.5 low vs last weeks' 1504.5 ; lets hope it will turn into a double bottom....

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #241

                                Genmab is proud to be on the 2020NJBIZ BestPlacesNJ to work list: https://njbiz.com/best-places-to-work-in-nj-2020/

                                1 Reply Last reply
                                0
                                • nohopeN Offline
                                  nohopeN Offline
                                  nohope
                                  wrote on sidst redigeret af
                                  #242

                                  Hmm - mon ikke det er sådan en liste over - lidet at bestille og meget at fortjene top ti?

                                  1 Reply Last reply
                                  0
                                  • nohopeN Offline
                                    nohopeN Offline
                                    nohope
                                    wrote on sidst redigeret af
                                    #243

                                    Deres excellence, det maatte være et embede, hvorved der var meget at fortjene og lidet at bestille; thi dertil føler jeg mig mest oplagt.

                                    1 Reply Last reply
                                    0
                                    • SolsenS Offline
                                      SolsenS Offline
                                      Solsen
                                      wrote on sidst redigeret af
                                      #244

                                      Lol

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #245

                                        🙂

                                        1 Reply Last reply
                                        0
                                        • bongobobB Offline
                                          bongobobB Offline
                                          bongobob
                                          wrote on sidst redigeret af
                                          #246

                                          Se seneste slide ware fra Genmab side 33. DR5/DR5 er MEGET potent https://ir.genmab.com/static-files/50a5c114-5126-45a8-9d6f-17b883705a16

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger